Corcept Therapeutics (FRA:HTD) Current Accrued Expense: €33.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HTD Corcept Therapeutics Inc FRA:HTD
85 GF Score
Price €97.00
GF Value €57.81
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Corcept Therapeutics Current Accrued Expense?

Corcept Therapeutics FRA:HTD -2.67% 85 Current Accrued Expense is €33.1 Mil as of Jun. 2026. GuruFocus rates FRA:HTD with a GF Score™ of 85/100 and a GF Value™ of €57.81 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Corcept Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was €33.1 Mil.

Corcept Therapeutics's quarterly Current Accrued Expense increased from Dec. 2025 (€38.1 Mil) to Mar. 2026 (€41.2 Mil) but then declined from Mar. 2026 (€41.2 Mil) to Jun. 2026 (€33.1 Mil).

Corcept Therapeutics's annual Current Accrued Expense declined from Dec. 2023 (€36.2 Mil) to Dec. 2024 (€35.5 Mil) but then increased from Dec. 2024 (€35.5 Mil) to Dec. 2025 (€38.1 Mil).

Corcept Therapeutics Current Accrued Expense Related Terms

Corcept Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Current Accrued Expense Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.08 30.12 36.21 35.54 38.06

Corcept Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.29 31.73 38.06 41.24 33.09
FRA:HTD
85GF Score
Corcept Therapeutics Inc FRA:HTD
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €33.1 Mil mean?
Corcept Therapeutics (FRA:HTD) has a Current Accrued Expense of €33.1 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Current Accrued Expense too high?
Corcept Therapeutics' current Current Accrued Expense is €33.1 Mil. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Current Accrued Expense compare to APGE and KRYS?
Corcept Therapeutics' Current Accrued Expense of €33.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Current Accrued Expense is €33.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €57.81, compared to a current price of €97.00 — trading 67.8% above its estimated fair value. The current Current Accrued Expense is €33.1 Mil. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current Current Accrued Expense is €33.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €97.00 is trading 67.8% above its estimated GF Value™ of €57.81. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:HTD:

  • Current Accrued Expense: €33.1 Mil
  • GF Value™: €57.81 vs. price of €97.00 (67.8% above fair value)
  • GF Score™: 85/100 with 9 warning signs

No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Other Exchanges CORT:USA1CORT:Italy0I3Q:UK
Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score

Get the complete analysis for FRA:HTD

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€97.00
Price
€57.81
GF Value